The HPV vaccine programme aims at girls $9\text{-}14$ years old, ideally before any sexual exposure. WHO's SAGE and several national programmes have moved to a $\textit{single-dose}$ schedule for this band, and the vaccine reliably triggers strong, high-titre immune responses.
The statement that fails scrutiny is the promise of $\textit{complete, 100\%}$ protection. The available vaccines neutralise the dominant oncogenic strains - types 16 and 18 cause roughly $70\%$ of cervical cancers, with extra coverage in the nonavalent product - but they cannot block every high-risk HPV type. So the protection is substantial yet partial, which is precisely why women must keep up with cervical screening.
\[\boxed{\text{"100\% complete protection" is the INCORRECT statement}}\]